Why the study?
Does detection of silent cerebrovascular disease refine risk stratification in hypertensive patients?
Does detection of silent cerebrovascular disease refine risk stratification in hypertensive patients?
Silent cerebrovascular disease serves as an independent prognostic marker for target-organ damage in hypertensive patients.
SCD detection may refine hypertensive risk stratification; leaves open prospective validation of clinical impact.
These data suggest that SCD should be recognized as an additional, independent and prognostically relevant marker of preclinical hypertensive target-organ damage.
No takes yet. Share an insight, caveat, or question.
Henskens et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: